Author response: Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus

  • Elan L. Guterman, Neurologist, University of California, San Francisco
  • Joseph K. Sanford, Neurologist, University of California, San Francisco
  • John P. Betjemann, Neurologist, Kaiser Permanente
  • Li Zhang, Statistics, University of California, San Francisco
  • James F. Burke, Neurologist, University of Michigan
  • Daniel H Lowenstein, Neurologist, University of California, San Francisco
  • S. Andrew Josephson, Neurologist, University of California, San Francisco
  • Karl A. Sporer, Emergency Medicine, University of California, San Francisco
Submitted January 06, 2021

We thank Dr. Kellinghaus et al. for sharing their experience of a large cohort of patients with status epilepticus in Europe. Their finding that patients in the SENSE registry are similarly not receiving the recommended initial benzodiazepine dose highlights the systemic nature of the problem: patients with status epilepticus are being undertreated.

We are in the midst of expanding our work to examine status epilepticus treatment across multiple pre-hospital systems in the United States, and reiterate the urgency and importance of better understanding this knowledge-practice gap.

Disclosure

The authors report no relevant disclosures. Contact journal@neurology.org for full disclosures.  

Reference

  1. Guterman EL, Sanford JK, Betjemann JP, et al. Prehospital midazolam use and outcomes among patients with out-of-hospital status epilepticus. Neurology. 2020;95(24):e3203-e3212. doi:10.1212/WNL.0000000000010913

Navigate back to article